Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Don Dizon MD
To determine the maximum tolerated dose (MTD) and dose-limitingtoxicities of intraperitoneal (IP) bortezomib (BTZ) when administeredwith intraperitoneal carboplatin in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer that is persistent or recurrent and who have failed primary therapy and at least one second-line therapy.
To examine the safety of administering BTZ in combination with carboplatin by the IP route.
Women with epithelial ovarian, fallopian tube, or primary peritoneal cancer that is persistent or recurrentand who have failed primary therapy and at least one second-line therapy.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.